Evaluation of a pen injector system for growth hormone treatment.
Department of Paediatrics, University of Auckland, New Zealand.
The increasing use of human growth hormone (hGH) treatment has resulted in the introduction of a number of alternative delivery systems to conventional syringe and needle administration. We examined patients' evaluation of a new delivery system, the Kabipen (Kabi-Vitrum). We also assessed the accuracy of hGH delivery by the Kabipen. Of the 77 survey respondents 13 had used only the Kabipen, 14 the syringe only, and 50 had used both systems. Altogether 46 (92%) of those who had used both systems preferred the Kabipen. Children over 10 years were more likely to self administer hGH with the Kabipen (64%) than syringe (25%). Patient instructions, convenience of use, and comfort of use were rated better for the Kabipen than syringe. With a dose setting of 2 units the Kabipen delivered a mean (SD) of 1.997 (0.073) units with 102.5% recovery from a unit cartridge. In summary the Kabipen is an accurate device clearly preferred by the majority of hGH recipients surveyed.
This article has been cited by other articles:
-
Bareille, P, MacSwiney, M, Albanese, A, De Vile, C, Stanhope, R
(1997). Growth hormone treatment without a needle using the Preci-Jet 50 transjector. Arch. Dis. Child.
76: 65-67
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



